Companies · Biotechnology

IceCure Medical Ltd.

CAESAREA · Biotechnology

Diligence memoA one-page analyst read on IceCure Medical Ltd. — recommendation, valuation, rhythm, risks.
$8.0M
Total raised · real
2
Rounds
1.0×
Latest step-up
Top 49%
Sector rank · raised
Seed
Latest stage · inferred · Thu Mar 26 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

IceCure Medical Ltd. looks over-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.63× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era.
Active
  • Last raise 3 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

IceCure Medical Ltd. is one of 4293 Biotechnology companies tracked from CAESAREA. By capital raised it ranks mid-pack (ahead of 52% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$1M–$5M
Issuer revenue
Rule 506(b)
Reg D exemption
5
Investors (latest)
2026-03-26
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2013-08-28 Raised $4.0M (real) Modeled valuation $178M (est)$4.0M$178MSeed2013Seed · 2026-03-26 Raised $4.0M (real) Modeled valuation $7.4M (est)$4.0M$7.4MSeed2026+$4.0MCumulative $8.0M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$4.0M · 2013
Seed extension$4.0M · 2026

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$7.4M
Base estimate est.
$2.9M
Conservative case
$12.4M
Upside case
$20.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $177.6M · 2013-08-282013Seed · modeled $7.4M · 2026-03-262026
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
0.3 yr
Elapsed time used
0.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
151 mo
Avg between rounds
$636K/yr
Capital velocity
12.8 yr
On record since
2013
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.1× above median
This company$8.0M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 2.3× above median
This company$4.0M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$7.4M
Sector median$64.2M

Raised more than 52% of sector peers (real $). Modeled value above 15% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #22 of 99.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0M$10.0MCapital raised (log)Carna Inc. · Seed Raised $3.4M · modeled $12.4M (est)NRX Pharmaceuticals, Inc. · Seed Raised $3.5M · modeled $12.3M (est)Vicora, Inc. · Seed Raised $3.4M · modeled $11.9M (est)MH3D, Inc. · Seed Raised $3.3M · modeled $11.9M (est)Oral Genome Corp. · Seed Raised $3.1M · modeled $11.2M (est)Synlico Inc. · Seed Raised $5.2M · modeled $10.1M (est)Auxilium Biotechnologies Inc. · Seed Raised $7.2M · modeled $9.7M (est)Silexion Therapeutics Corp · Seed Raised $3.6M · modeled $9.6M (est)Bodark Investment Group LP · Seed Raised $3.3M · modeled $9.4M (est)Sower Solas I Sidecar III, LLC · Seed Raised $3.5M · modeled $9.3M (est)Sift Biosciences, Inc. · Seed Raised $3.8M · modeled $8.5M (est)SiVEC Biotechnologies, Inc. · Seed Raised $3.3M · modeled $8.4M (est)IceCure Medical Ltd. (this company) Raised $8.0M · modeled $7.4M (est)IceCure Medical Ltd.
CompanyStageRaised · realValue · estvs peer med.
Carna Inc.Seed$3.4M$12.4M2.72×
NRX Pharmaceuticals, Inc.Seed$3.5M$12.3M2.70×
Vicora, Inc.Seed$3.4M$11.9M2.61×
MH3D, Inc.Seed$3.3M$11.9M2.61×
Oral Genome Corp.Seed$3.1M$11.2M2.45×
Synlico Inc.Seed$5.2M$10.1M2.22×
Auxilium Biotechnologies Inc.Seed$7.2M$9.7M2.13×
Silexion Therapeutics CorpSeed$3.6M$9.6M2.10×
Bodark Investment Group LPSeed$3.3M$9.4M2.06×
Sower Solas I Sidecar III, LLCSeed$3.5M$9.3M2.05×
Sift Biosciences, Inc.Seed$3.8M$8.5M1.85×
SiVEC Biotechnologies, Inc.Seed$3.3M$8.4M1.85×
IceCure Medical Ltd. this companySeed$8.0M$7.4M1.63×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$4.0M2013-08-28$20.0M$177.6M85%
Seed$4.0M2026-03-26$20.0M$7.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$4.0M2013-08-28
    • First recorded raise — entered as Seed.
    • 16 investors on this round.
  2. Seed$4.0M2026-03-26
    • Raised again after 151 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • Revenue band moved $0–$1M → $1M–$5M.
    • Switched to Rule 506(b) (was Rule 06).
    • 5 investors on this round.
Intelligence
2038 ~Q4
Modeled next raise · ~151mo cadence
$4.0M
Modeled next size est.range $4.0M$6.4M
1.0×
Last step-up
$636K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Ron Mayron5 other2026-03
Doron Birger2 other2013-08
Doron Cohen2 other2013-08
Yaacov Goldman2 other2013-08
Adi Goldin1 other2013-08
Elka Nir1 other2013-08
Eyal Shamir1 other2026-03
Merav Nir Dotan1 other2026-03
Shad Good1 other2026-03
Sharon Levita1 other2026-03
Shay Levav1 other2026-03
Tlalit Bussi Tel-Tzure1 other2026-03
Vincent Chun Hung Chan1 other2026-03
William Irby1 other2013-08
Yang Huang1 other2026-03
Yonatan Malca1 other2026-03
Alon Dumanis2013-08
Elizabeth Sadka2013-08
Meirav Dudek2013-08
Naum Muchnik2026-03
Nir Bachman2013-08
Oded Tamir2013-08
Ronen Tsimerman2026-03
Yehezkel Himelfarb2013-08
Registry & provenance

IceCure Medical Ltd. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1584371
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
IceCure Medical Ltd.BiotechnologySeries B$16.5M$50.3Mnetwork9 shared operators · same sector
Entera Bio Ltd.BiotechnologySeries A$22.2M$44.9Mnetwork2 shared operators · same sector
Medigus Ltd.BiotechnologySeries A$8.6M$108.7Mnetwork1 shared operator · same sector
Apexian Pharmaceuticals, Inc.BiotechnologySeed$7.7M$6.7Msame sector · same stage
ProPhase Labs, Inc.BiotechnologySeed$8.4M$8.1Msame sector · same stage
Comera Life Sciences Holdings, Inc.BiotechnologySeed$7.5M$9.6Msame sector · same stage
Amplified Sciences, Inc.BiotechnologySeed$7.4M$7.8Msame sector · same stage
C4 Imaging, LLCBiotechnologySeed$7.3M$9.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Gliacure, Inc.BiotechnologySeries A$57.0M84%
NextCure, Inc.BiotechnologySeries C$113.9M84%
BrainTrust BIO Inc.BiotechnologyPre-Seed$14.2M84%
Azure Health Technology LtdBiotechnologyPre-Seed$19.5M84%
Akonni Biosystems IncBiotechnologySeries A$64.2M84%
Biocurity Pharmaceuticals Inc.BiotechnologySeed$13.3M84%
Magnus Medical, Inc.BiotechnologySeries C$153.8M84%
Kubanda Cryotherapy, Inc.BiotechnologyPre-Seed$1.0M84%
Frequently asked
How much funding has IceCure Medical Ltd. raised?
IceCure Medical Ltd. has raised approximately $8.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is IceCure Medical Ltd.'s estimated valuation?
Provath's modeled valuation for IceCure Medical Ltd. is approximately $7.4M (modeled range $2.9M–$12.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is IceCure Medical Ltd. at?
IceCure Medical Ltd.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Thu Mar 26.
What does IceCure Medical Ltd. do and where is it based?
IceCure Medical Ltd. operates in the Biotechnology sector, based in CAESAREA.
Explore related

See where IceCure Medical Ltd. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at IceCure Medical Ltd., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.